Hikma Sharpens Focus On COVID-19 Demand

Maintains Financial Guidance Amid Coronavirus Challenges And Uncertainty

Hikma says it is prioritizing the production and delivery of medicines that are in the highest demand amid the COVID-19 pandemic, as the firm has provided a trading update that maintains its sales forecasts in the face of “challenging market conditions” and uncertainty.

Demand
Hikma is focused on meeting the highest demand amid the coronavirus pandemic • Source: Shutterstock

Hikma says it has made a strong start to 2020 across all three of its business segments – comprising injectables; non-injectable generics and specialty in the US; and the Middle East and North Africa branded segment – as it prioritizes the supply of medicines that are most in demand amid the COVID-19 pandemic.

The firm has reiterated its full-year guidance despite CEO Siggi Olafsson acknowledging “challenging market conditions that have arisen as a...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Earnings

More from Business